Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Update

Psyence Biomedical Ltd. (NASDAQ:PBM) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 145,422 shares, an increase of 116.0% from the January 15th total of 67,332 shares. Based on an average daily trading volume, of 618,782 shares, the short-interest ratio is currently 0.2 days. Approximately 14.8% of the shares of the stock are short sold. Approximately 14.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 618,782 shares, the short-interest ratio is currently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Psyence Biomedical stock. Virtu Financial LLC bought a new stake in Psyence Biomedical Ltd. (NASDAQ:PBM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,325 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.55% of Psyence Biomedical at the end of the most recent quarter. 77.44% of the stock is owned by hedge funds and other institutional investors.

Psyence Biomedical Stock Down 5.1%

NASDAQ PBM traded down $0.15 during trading hours on Thursday, hitting $2.81. 82,579 shares of the company were exchanged, compared to its average volume of 284,666. Psyence Biomedical has a 52 week low of $2.54 and a 52 week high of $74.94. The stock has a 50-day moving average price of $5.85 and a 200 day moving average price of $15.35. The stock has a market cap of $2.87 million, a PE ratio of 0.11 and a beta of 0.32.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Psyence Biomedical in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.